Skip to main content
. 2021 Apr 9;8:603501. doi: 10.3389/fcvm.2021.603501

Figure 3.

Figure 3

Observed annual rate of thromboembolic events and bleeding events vs. the expected rate based on CHA2DS2-VASC2 score and HAS-BLED risk: (A) Control group; (B) Thrombocytopenia group.